Glibenclamide is a second-generation sulfonylurea developed for type 2 diabetes targeting the SUR1-TRPM4 channel, and glibenclamide inhibits SUR1-TRPM4 channel upregulation after CNS damage. Here, TRPM4 is linked to type 2 diabetes mellitus.